文献速递肝病

乌干达中南部代谢功能障碍相关脂肪性肝病的患病率与危险因素:一项横断面调查

Prevalence and risk factors of metabolic dysfunction-associated steatotic liver disease in south Central Uganda: A cross-sectional survey.
PubMed 文献 · Aliment Pharmacol Ther · 2024-03-08

该研究于2016年5月至2018年5月在乌干达中南部37个社区开展横断面调查,纳入759名HIV感染者与704名HIV阴性者(35-49岁),采用脂肪肝指数估计MASLD患病率。MASLD患病率女性为14%、男性为8%,晚期肝纤维化患病率估计低于1%;调整混杂因素后,女性(OR=2.1,95%CI 1.4-3.3)与MASLD较高几率相关,HIV感染与MASLD的关联处于临界水平(OR=1.4,95%CI 1.0-2.0)。

要点

  • 乌干达中南部35-49岁人群中,MASLD患病率女性为14%、男性为8%。
  • 晚期肝纤维化患病率估计低于1%。
  • 调整混杂因素后,女性与MASLD较高几率相关(OR=2.1,95%CI 1.4-3.3);HIV感染与MASLD的关联处于临界水平(OR=1.4,95%CI 1.0-2.0)。

核心结论

  • 在乌干达一个相对年轻的队列中,14%的女性和8%的男性患有MASLD。
  • 多变量分析提示HIV与MASLD之间可能存在关联。
  • 这些数据首次利用基于人群的队列数据描述了撒哈拉以南非洲MASLD的人群层面负担。

研究设计与样本

  • 研究为横断面调查,于2016年5月至2018年5月在乌干达中南部37个社区收集数据。
  • 共纳入759名HIV感染者和704名HIV阴性参与者,年龄35-49岁。
  • 采用脂肪肝指数估计MASLD患病率,采用动态天冬氨酸与丙氨酸氨基转移酶比值估计晚期肝纤维化。
  • 收集社会人口学、HIV及心血管疾病危险因素数据,采用多变量逻辑回归分析HIV、心血管疾病危险因素与MASLD的关联。

主要发现

  • MASLD总体患病率女性为14%、男性为8%。
  • 晚期肝纤维化患病率估计低于1%。
  • HIV感染者中MASLD患病率女性为15%、男性为9%;HIV阴性者中女性为13%、男性为6%。
  • 调整混杂因素后,女性与MASLD较高几率相关(OR=2.1;95%CI 1.4-3.3)。
  • HIV感染与MASLD的关联处于临界水平(OR=1.4;95%CI 1.0-2.0)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite numerous risk factors and serious consequences, little is known about metabolic dysfunction-associated steatotic liver disease (MASLD) at population level in Africa. AIM: The aim of the study was to estimate the prevalence and risk factors of MASLD in people living with and without HIV in Uganda. METHODS: We collected data from 37 communities in South Central Uganda between May 2016 and May 2018. We estimated MASLD prevalence using the fatty liver index and advanced liver fibrosis using the dynamic aspartate-to-alanine aminotransferase ratio. We collected additional data on sociodemographics, HIV and cardiovascular disease (CVD) risk factors. We used multivariable logistic regression to determine the association between HIV, CVD risk factors and MASLD. RESULTS: We included 759 people with HIV and 704 HIV-negative participants aged 35-49. MASLD prevalence was 14% in women and 8% in men; advanced liver fibrosis prevalence was estimated to be <1%. MASLD prevalence was more common in women (15% vs. 13%) and men (9% vs. 6%) with HIV. Being female (odds ratio [OR] = 2.1; 95% confidence interval [CI] = 1.4-3.3) was associated with a higher odds of MASLD after adjustment for confounders; HIV infection was borderline associated with MASLD (OR = 1.4; 95% CI: 1.0-2.0). CONCLUSIONS: In a relatively young cohort in Uganda, 14% of women and 8% of men had MASLD. There was an indication of an association between HIV and MASLD in multivariable analysis. These data are the first to describe the population-level burden of MASLD in sub-Saharan Africa using data from a population-based cohort.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Enriquez R, Homsi M, Ssekubugu R, et al. Prevalence and risk factors of metabolic dysfunction-associated steatotic liver disease in south Central Uganda: A cross-sectional survey. Aliment Pharmacol Ther. 2024. PMID: 38459720. doi:10.1111/apt.17931

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。